Immunoinformatics studies and design of a novel multi-epitope peptide vaccine against Toxoplasma gondii based on calcium-dependent protein kinases antigens through an in-silico analysis.

IF 2.1 Q4 IMMUNOLOGY Clinical and Experimental Vaccine Research Pub Date : 2024-04-01 Epub Date: 2024-04-30 DOI:10.7774/cevr.2024.13.2.146
Ali Dalir Ghaffari, Fardin Rahimi
{"title":"Immunoinformatics studies and design of a novel multi-epitope peptide vaccine against <i>Toxoplasma gondii</i> based on calcium-dependent protein kinases antigens through an <i>in-silico</i> analysis.","authors":"Ali Dalir Ghaffari, Fardin Rahimi","doi":"10.7774/cevr.2024.13.2.146","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Infection by the intracellular apicomplexan parasite <i>Toxoplasma gondii</i> has serious clinical consequences in humans and veterinarians around the world. Although about a third of the world's population is infected with <i>T. gondii</i>, there is still no effective vaccine against this disease. The aim of this study was to develop and evaluate a multimeric vaccine against <i>T. gondii</i> using the proteins calcium-dependent protein kinase (CDPK)1, CDPK2, CDPK3, and CDPK5.</p><p><strong>Materials and methods: </strong>Top-ranked major histocompatibility complex (MHC)-I and MHC-II binding as well as shared, immunodominant linear B-cell epitopes were predicted and linked using appropriate linkers. Moreover, the 50S ribosomal protein L7/L12 (adjuvant) was mixed with the construct's N-terminal to increase the immunogenicity. Then, the vaccine's physicochemical characteristics, antigenicity, allergenicity, secondary and tertiary structure were predicted.</p><p><strong>Results: </strong>The finally-engineered chimeric vaccine had a length of 680 amino acids with a molecular weight of 74.66 kDa. Analyses of immunogenicity, allergenicity, and multiple physiochemical parameters indicated that the constructed vaccine candidate was soluble, non-allergenic, and immunogenic, making it compatible with humans and hence, a potentially viable and safe vaccine candidate against <i>T. gondii</i> parasite.</p><p><strong>Conclusion: </strong><i>In silico</i>, the vaccine construct was able to trigger primary immune responses. However, further laboratory studies are needed to confirm its effectiveness and safety.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 2","pages":"146-154"},"PeriodicalIF":2.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091428/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2024.13.2.146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Infection by the intracellular apicomplexan parasite Toxoplasma gondii has serious clinical consequences in humans and veterinarians around the world. Although about a third of the world's population is infected with T. gondii, there is still no effective vaccine against this disease. The aim of this study was to develop and evaluate a multimeric vaccine against T. gondii using the proteins calcium-dependent protein kinase (CDPK)1, CDPK2, CDPK3, and CDPK5.

Materials and methods: Top-ranked major histocompatibility complex (MHC)-I and MHC-II binding as well as shared, immunodominant linear B-cell epitopes were predicted and linked using appropriate linkers. Moreover, the 50S ribosomal protein L7/L12 (adjuvant) was mixed with the construct's N-terminal to increase the immunogenicity. Then, the vaccine's physicochemical characteristics, antigenicity, allergenicity, secondary and tertiary structure were predicted.

Results: The finally-engineered chimeric vaccine had a length of 680 amino acids with a molecular weight of 74.66 kDa. Analyses of immunogenicity, allergenicity, and multiple physiochemical parameters indicated that the constructed vaccine candidate was soluble, non-allergenic, and immunogenic, making it compatible with humans and hence, a potentially viable and safe vaccine candidate against T. gondii parasite.

Conclusion: In silico, the vaccine construct was able to trigger primary immune responses. However, further laboratory studies are needed to confirm its effectiveness and safety.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于钙依赖性蛋白激酶抗原的免疫信息学研究和新型多表位肽刚地弓形虫疫苗的设计(通过实验室内分析)。
目的:细胞内的弓形虫寄生虫感染会给人类和世界各地的兽医带来严重的临床后果。虽然全球约有三分之一的人口感染了弓形虫,但目前仍没有针对这种疾病的有效疫苗。本研究的目的是利用钙依赖性蛋白激酶(CDPK)1、CDPK2、CDPK3 和 CDPK5 蛋白,开发并评估针对淋病的多聚酶疫苗:使用适当的连接体预测并连接了排名靠前的主要组织相容性复合体(MHC)-I 和 MHC-II 结合以及共享的免疫优势线性 B 细胞表位。此外,50S 核糖体蛋白 L7/L12 (佐剂)与构建体的 N 端混合,以增加免疫原性。然后,对疫苗的理化特性、抗原性、致敏性、二级和三级结构进行了预测:结果:最终设计的嵌合疫苗长度为 680 个氨基酸,分子量为 74.66 kDa。免疫原性、致敏性和多种理化参数的分析表明,构建的候选疫苗具有可溶性、非致敏性和免疫原性,使其与人类相容,因此是一种潜在可行且安全的预防淋球菌寄生的候选疫苗:结论:该疫苗构建体能够引发初级免疫反应。然而,还需要进一步的实验室研究来确认其有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
期刊最新文献
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients. Root causes of low influenza vaccination coverage rates among nurses working in a tertiary care university hospital in Turkey: result of a study using nominal group technique. Safety and immunogenicity of an inactivated vero cell-based rabies vaccine (Rabivax-S) in pre-exposure prophylaxis schedule in Vietnam. Vaccination status of elite athletes in the German Armed Forces: a retrospective descriptive overview. A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1